Drugs / Recombinant Flt3 Ligand
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04616248 Background | Jan 2023 → Jan 2027 expected | basal cell carcinoma, bone sarcoma, breast carcinoma, cutaneous neuroendocrine carcinoma +3 | University of Southern California | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Flt3 Ligand | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04616248 ↗ |
| Modality | Protein / enzyme biologic | “recombinant Flt3 ligand” NCT04616248 ↗ |
| Route | Other | “Given IT” NCT04616248 ↗ |